This IPO has massive market potential as China's GLP-1 drug market is projected to exceed RMB 10 billion annually, with obesity and diabetes rates surging.
I also like that its Founder Wang Qinghua is a former professor at the University of Toronto Canada and is a national expert on metabolic diseases.
I believe that this IPO will be oversubscribed due to its tremendous potential for exponential growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- Frosty4everΒ·08-10TOPneed to be certified investor to subscribe. feasible to invest in first day of trading?1Report
- Gloria112Β·08-08TOPThis sounds promising1Report
- zippixoΒ·08-08TOPExciting potential1Report